VTGN - VistaGen Therapeutics, Inc. Stock Price and Quote

VTGN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.31	Insider Own	0.30%	Shs Outstand	206.81M	Perf Week	40.85%
Market Cap	55.80M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	197.13%	Shs Float	205.00M	Perf Month	119.62%
Income	-64.70M	PEG	-	EPS next Q	-0.07	Inst Own	28.90%	Short Float / Ratio	6.05% / 1.89	Perf Quarter	149.34%
Sales	-0.19M	P/S	-	EPS this Y	49.90%	Inst Trans	-60.56%	Short Interest	12.40M	Perf Half Y	108.13%
Book/sh	0.14	P/B	2.14	EPS next Y	12.90%	ROA	-97.80%	Target Price	-	Perf Year	-77.45%
Cash/sh	0.19	P/C	1.58	EPS next 5Y	-	ROE	-117.40%	52W Range	0.08 - 1.79	Perf YTD	213.01%
Dividend	-	P/FCF	-	EPS past 5Y	30.70%	ROI	-73.90%	52W High	-81.99%	Beta	0.91
Dividend %	-	Quick Ratio	6.10	Sales past 5Y	-2.40%	Gross Margin	-	52W Low	319.79%	ATR	0.03
Employees	34	Current Ratio	6.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	81.74	Volatility	18.80% 15.29%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-24.00%	Profit Margin	-	Rel Volume	3.18	Prev Close	0.30
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 10 AMC	Payout	-	Avg Volume	6.56M	Price	0.32
Recom	2.30	SMA20	66.08%	SMA50	115.07%	SMA200	-28.14%	Volume	2,466,001	Change	7.47%

Jul-22-22

Downgrade

William Blair

Outperform → Mkt Perform

Jul-22-22

Downgrade

Robert W. Baird

Outperform → Neutral

Jul-22-22

Downgrade

Jefferies

Buy → Hold

May-20-21

Initiated

Robert W. Baird

Outperform

Feb-18-21

Initiated

Jefferies

Buy

Jan-04-21

Upgrade

William Blair

Mkt Perform → Outperform

Jun-27-18

Initiated

Maxim Group

Buy

Feb-08-18

Reiterated

Chardan Capital Markets

Buy

$30 → $22

Mar-28-17

Initiated

Maxim Group

Buy

Feb-06-23 09:09AM	Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023 Business Wire +7.47%
Feb-02-23 09:00AM	Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition Business Wire +8.91%
Jan-24-23 08:30AM	Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder Business Wire
Jan-19-23 08:30AM	Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023 News Direct -10.14%
Jan-10-23 08:30AM	Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety Business Wire +5.80%
08:30AM	Loading…
Dec-30-22 08:30AM	Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder Business Wire +8.65%
Dec-21-22 10:56AM	Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition Benzinga
08:30AM	Vistagen to Acquire Pherin Pharmaceuticals Business Wire
Dec-16-22 08:35AM	KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing GlobeNewswire +30.09%
Dec-13-22 08:35AM	KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th GlobeNewswire
Dec-06-22 08:30AM	Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder Business Wire +5.38%
Nov-30-22 08:30AM	Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder Business Wire
Nov-17-22 08:30AM	Vistagen Announces Publication in Cells Demonstrating AV-101s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease Business Wire
Nov-15-22 12:00PM	What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock Zacks
Nov-10-22 06:45PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates Zacks +15.45%
04:30PM	Loading…
04:30PM	Vistagen Reports Second Quarter Financial Results and Provides Corporate Update Business Wire
Nov-04-22 08:30AM	Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022 Business Wire
Nov-03-22 08:30AM	Vistagen to Present at Stifel 2022 Healthcare Conference Business Wire
Oct-26-22 09:00AM	Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ Business Wire +5.89%
Oct-22-22 08:02AM	Shareholders Will Likely Find VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) CEO Compensation Acceptable Simply Wall St.
Oct-19-22 04:30PM	Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022 Business Wire
Oct-06-22 08:30AM	Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote "FOR" Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary Business Wire
Oct-03-22 08:30AM	Vistagen to Participate at Cantor Neurology & Psychiatry Conference Business Wire +5.52%
Sep-24-22 08:10AM	Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m Simply Wall St.
Sep-20-22 08:30AM	Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit Business Wire
Sep-19-22 08:30AM	Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects Business Wire -5.18%
Sep-09-22 08:30AM	Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences Business Wire +5.84%
Sep-08-22 02:24PM	Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial Benzinga +18.36%
08:00AM	Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis Business Wire
Aug-11-22 04:20PM	VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update Business Wire
08:30AM	Loading…
Aug-09-22 08:30AM	VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022 Business Wire -5.23%
Jul-22-22 09:06AM	VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study Benzinga -85.99%
08:00AM	VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B Business Wire
Jul-20-22 10:42AM	2 Strong Buy Penny Stocks That Could Go Boom TipRanks +14.89%
Jul-12-22 08:30AM	VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit Business Wire -6.12%
Jul-07-22 08:30AM	VistaGen to Participate at William Blair Biotech Focus Conference 2022 Business Wire +5.46%
Jun-23-22 05:35PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:20PM	VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update Business Wire
Jun-22-22 08:30AM	VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder Business Wire
Jun-17-22 08:30AM	VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022 Business Wire +5.16%
Jun-02-22 08:30AM	VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting Business Wire
May-31-22 05:20AM	Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock? Zacks +8.49%
May-27-22 08:30AM	VistaGen to Participate in Upcoming June Investor Conferences Business Wire
May-19-22 06:00PM	7 Cheap Biotech Stocks to Buy Now InvestorPlace
May-10-22 10:34AM	What You Need To Know About VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) Investor Composition Simply Wall St.
May-05-22 08:30AM	VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder Business Wire
May-02-22 08:00AM	VistaGen Appoints Reid Adler as Chief Legal Officer Business Wire
Apr-21-22 08:00AM	VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses Business Wire -7.33%
Apr-12-22 02:57PM	Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC Zacks
11:20AM	Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed Zacks
07:00AM	VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B Business Wire
Apr-07-22 12:05PM	Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer Zacks
Apr-05-22 12:08PM	Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion Zacks
Mar-24-22 08:00AM	VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference GlobeNewswire
Mar-19-22 08:38AM	We're Hopeful That VistaGen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely Simply Wall St.
Feb-10-22 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:20PM	VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Feb-07-22 08:00AM	VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022 GlobeNewswire
Feb-03-22 03:01PM	Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline Zacks
Nov-19-21 11:17AM	What Kind Of Investors Own Most Of VistaGen Therapeutics, Inc. (NASDAQ:VTGN)? Simply Wall St.
Nov-16-21 08:30AM	VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-14-21 08:53AM	10 Best Biotech Stocks Under $5 Insider Monkey
Nov-11-21 04:31AM	VISTAGEN THERAPEUTIC (VSTA) Q2 2022 Earnings Call Transcript Motley Fool
Nov-10-21 07:05PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:20PM	VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-21 03:01PM	Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know Zacks -6.54%
08:00AM	VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021 GlobeNewswire
Oct-14-21 12:18PM	VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial Benzinga
08:00AM	VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder GlobeNewswire
Oct-05-21 12:06PM	VistaGen Therapeutics Inc. Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity Benzinga
08:00AM	VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94Bs Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain GlobeNewswire
Sep-20-21 02:38PM	We're Interested To See How VistaGen Therapeutics (NASDAQ:VTGN) Uses Its Cash Hoard To Grow Simply Wall St. -6.04%
Sep-13-21 06:00AM	VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2 GlobeNewswire
Sep-08-21 08:00AM	VistaGen Therapeutics to Participate in Bairds 2021 Global Healthcare Conference GlobeNewswire
Aug-13-21 06:31AM	VISTAGEN THERAPEUTIC (VSTA) Q1 2022 Earnings Call Transcript Motley Fool
Aug-12-21 08:05PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:25PM	VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-21 04:05PM	VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021 GlobeNewswire
Aug-02-21 09:05AM	10 Cheapest Stocks on Robinhood Insider Monkey
08:00AM	VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Jul-22-21 08:00AM	VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors GlobeNewswire
Jul-21-21 08:28AM	Can You Imagine How Jubilant VistaGen Therapeutics' (NASDAQ:VTGN) Shareholders Feel About Its 263% Share Price Gain? Simply Wall St. +6.55%
Jul-09-21 08:30AM	VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021 GlobeNewswire
06:54AM	What Do VistaGens Newly Added Risk Factors Mean for Investors SmarterAnalyst
Jul-07-21 08:30AM	VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors GlobeNewswire
Jun-30-21 04:14PM	Why VistaGen Therapeutics Stock Jumped Today Motley Fool +17.54%
Jun-29-21 04:15PM	VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update GlobeNewswire -5.63%
Jun-25-21 08:00AM	VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021 GlobeNewswire
Jun-16-21 08:00AM	VistaGen Therapeutics Set to Join the Russell 2000® Index GlobeNewswire
May-26-21 08:00AM	VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder GlobeNewswire -11.45%
May-20-21 08:00AM	VistaGen Therapeutics to Present at Two Investor Conferences in June GlobeNewswire +12.17%
May-19-21 08:37AM	What Type Of Shareholders Make Up VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) Share Registry? Simply Wall St.
May-04-21 08:00AM	VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer GlobeNewswire
Apr-27-21 09:33AM	Novel Anxiety and Depression Approach by VistaGen Therapeutics Benzinga
08:00AM	VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors GlobeNewswire
Mar-31-21 10:30PM	VISTAGEN THERAPEUTIC (VSTA) Q4 2020 Earnings Call Transcript Motley Fool
Mar-22-21 08:30AM	VistaGens Poster Presentation at the Anxiety and Depression Association of Americas 2021 Annual Conference Differentiates PH94Bs Mechanism of Action from Highly-Addictive Benzodiazepines GlobeNewswire
Mar-16-21 07:46AM	VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March GlobeNewswire
Mar-11-21 08:30AM	VistaGens PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study GlobeNewswire +9.77%
08:17AM	New Strong Sell Stocks for March 11th Zacks

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GIN JERRY B	Director	Aug 18	Buy	0.18	100,000	17,870	100,000	Aug 22 05:12 PM
GIN JERRY B	Director	Aug 18	Buy	0.18	100,000	17,870	100,000	Aug 22 05:12 PM
Singh Shawn	CHIEF EXECUTIVE OFFICER	Aug 17	Buy	0.17	600,000	103,200	626,234	Aug 18 03:56 PM
Adler Reid G.	CHIEF LEGAL OFFICER	Aug 17	Buy	0.17	300,000	50,910	334,629	Aug 19 03:45 PM
Venrock Healthcare Capital Par	10% Owner	Jul 12	Sale	0.89	60,000	53,400	20,637,286	Jul 14 05:33 PM
Singh Shawn	CHIEF EXECUTIVE OFFICER	May 12	Option Exercise	1.00	100,000	100,000	148,998	May 16 01:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience